Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 2Thoracic 1Gynecologic 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 3Urethral Neoplasms 3Carcinoma, Transitional Cell 3Ureteral Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Liver Neoplasms 1Fallopian Tube Neoplasms 1Cholangiocarcinoma 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Ramucirumab × Genitourinary × Clear all
NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Eli Lilly and Company

Phase 1 Completed
175 enrolled 23 charts
GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT02426125 2023-08-21

RANGE

Eli Lilly and Company

Phase 3 Completed
530 enrolled 22 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡